Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Healthcare Biotechnology

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > 2.22 All Time High w/ Close House Positions

<< Previous

Bullboard Posts

Next >>

Comment by GoldenArmon Oct 12, 2021 4:36pm

111 Views

Post# 33998740

RE:RE:2.22 All Time High w/ Close House Positions

Another up day with good volume but not the the that says big boys are here. This company was a no brainer when I bought it in April and now that I'm close to 100% I have no desire to sell a single share. This stock ARCh is under valued. Tomorrow I hope for more volume and a new high 10% plus gain over today.

<< Previous

Bullboard Posts

Next >>

3 Mid-Sized Stocks to Consider This Season